Endothelial Progenitor Cells and Pulmonary Arterial Hypertension

被引：46

作者：

Chen, Haiying ^{[1
,2
,3
]}

Strappe, Padraig ^{[5
]}

Chen, Shuangfeng ^{[1
,2
,3
]}

Wang, Le-Xin ^{[3
,4
,5
]}

机构：

[1] Shandong Univ, Liaocheng Peoples Hosp, Cent Lab, Liaocheng 252000, Shandong, Peoples R China

[2] Shandong Univ, Liaocheng Peoples Hosp, Key Lab Oral Maxillofacial Head & Neck Med Biol, Liaocheng 252000, Shandong, Peoples R China

[3] Shandong Univ, Affiliated Liaocheng Peoples Hosp, Liaocheng 252000, Shandong, Peoples R China

[4] Shandong Univ, Liaocheng Peoples Hosp, Dept Cardiol, Liaocheng 252000, Shandong, Peoples R China

[5] Charles Sturt Univ, Sch Biomed Sci, Wagga Wagga, NSW 2650, Australia

来源：

HEART LUNG AND CIRCULATION | 2014年 / 23卷 / 07期

基金：

中国国家自然科学基金;

关键词：

Pulmonary arterial hypertension (PAH); Endothelial progenitor cells (EPCs); Cell therapy; Vascular remodelling; Pulmonary disease; SMOOTH-MUSCLE-CELLS; PROTEIN-RECEPTOR II; NITRIC-OXIDE; THERAPEUTIC TARGETS; OXIDATIVE STRESS; VASCULAR-TONE; GENE-TRANSFER; STEM-CELLS; BLOOD-FLOW; DISEASE;

D O I：

10.1016/j.hlc.2014.02.007

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Pulmonary arterial hypertension (PAR) is a progressive disease characterised by lung endothelial cell dysfunction and vascular remodelling. A number of studies now suggest that endothelial progenitor cells (EPCs) may induce neovascularisation and could be a promising approach for cell based therapy for PAR. On the contrary EPCs may contribute to pulmonary vascular remodelling, particularly in end-stage pulmonary disease. This review article will provide a brief summary of the relationship between PAH and EPCs, the application of the EPCs to PAH and highlight the potential clinical application of the EPCs cell therapy to PAR.

引用

页码：595 / 601

页数：7

共 98 条

[1]

Genetic, cellular and molecular mechanisms of pulmonary arterial hypertension [J].